Clinical Trials Logo

Mismatch Repair Deficiency clinical trials

View clinical trials related to Mismatch Repair Deficiency.

Filter by:

NCT ID: NCT06362369 Recruiting - Colorectal Cancer Clinical Trials

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Start date: May 20, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b

NCT ID: NCT06215677 Recruiting - Colon Cancer Clinical Trials

Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer

NITDC
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adjacent organs in T4 colon cancer patients with dMMR.

NCT ID: NCT06034860 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Start date: November 1, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose escalation and expansion study of MT-8421 (an Engineered Toxin Body (ETB)) as monotherapy and in combination with nivolumab in patients with selected advanced solid cancer types. MT-8421 is an investigational drug that specifically targets and depletes cytotoxic T-lymphocytes-associated protein 4 (CTLA-4) expressing cells in an effort to directly dismantle the tumor microenvironment for the treatment of patients with advanced solid tumors.

NCT ID: NCT05729646 Recruiting - Clinical trials for Adenocarcinoma of the Stomach

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Start date: May 31, 2023
Phase: Phase 2
Study type: Interventional

This study is a prospective, multi-center, randomized controlled phase II trial to compare the efficacy of perioperative SOX plus toripalimab, toripalimab monotherapy with SOX regimen in participants with dMMR locally advanced gastric or esophagogastric junction adenocarcinoma

NCT ID: NCT05257057 Active, not recruiting - Endometrial Cancer Clinical Trials

Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome

Start date: May 8, 2019
Phase:
Study type: Observational

Given that there is a significant prevalence of Lynch syndrome among patients with endometrial cancer (about 5% of patients with endometrial cancer), and given there is a known risk of endometrial cancer among patients with endometrial hyperplasia (40% risk of pre-existing occult cancer with endometrial intraepithelial neoplasia), it is hypothesized that a diagnosis of endometrial hyperplasia may herald on-going risk of harboring a Lynch Syndrome gene mutation. The purpose of this study is to examine endometrial hyperplasia specimens and compare the frequency of Lynch Syndrome gene mutations between endometrial hyperplasia and endometrial cancer subjects. This will provide a rationale and opportunity for earlier screening, and reduce colon cancer morbidity and mortality secondary to the Lynch syndrome gene.

NCT ID: NCT05098132 Recruiting - Gastric Cancer Clinical Trials

Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

Start date: January 25, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

NCT ID: NCT04906382 Terminated - Lynch Syndrome Clinical Trials

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Start date: July 1, 2021
Phase: Early Phase 1
Study type: Interventional

This clinical trial evaluates the effect of tislelizumab in treating patients with mismatch repair deficient endometrial cancer that has come back (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing DNA errors and damage. Mismatch repair deficient tumors (dMMR) may have difficulty repairing DNA mutations during replication that may affect tumor's response to therapy. Immunotherapy with monoclonal antibodies, such as tislelizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tislelizumab may help treat patients with mismatch repair deficient endometrial cancer.

NCT ID: NCT04482608 Completed - Clinical trials for Colorectal Cancer Metastatic

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

Start date: September 1, 2019
Phase:
Study type: Observational

Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC). The efficacy and survival of patients with dMMR/MSI-H status received palliative chemotherapy have not clear yet. In this study, the investigators observed the efficacy and survival of dMMR/MSI-H status mCRC patients received palliative first-line chemotherapy.

NCT ID: NCT04001101 Withdrawn - Colorectal Cancer Clinical Trials

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Start date: October 10, 2019
Phase: Phase 2
Study type: Interventional

To determine if the out-of-field ORR is improved with the addition of radiation therapy to anti-PD-1 for patients with MSI-H/dMMR metastatic solid tumors. Determine the rates of in-field tumor control, disease control (stable disease, partial response, complete response), durability of disease response, progression-free survival, overall survival, and to assess quality of life and toxicity. Determine the chronology and profile of the radiation-associated immune response.

NCT ID: NCT03935893 Recruiting - Colorectal Cancer Clinical Trials

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Start date: December 3, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite unstable cancers, and 10.) patients who have exhausted conventional systemic therapy options by using the objective response rate (ORR).